GlaxoSmithKline Pharmaceuticals has launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is the first once daily single-inhaler triple therapy (SITT) in India for COPD patients.
The product launch comes after the Drugs Controller General of India (DCGI) approved the use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.
GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: